Skip to main content
| News

Engimmune Therapeutics banks 15.5 million Swiss francs

03.05.2022

Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies against cancer after receiving seed financing to the tune of 15.5 million Swiss francs. The company was founded and built up with the help of the biotech accelerator and incubator BaseLaunch.

Engimmune Therapeutics has received investments totaling 15.5 million Swiss francs for the development of novel T-cell receptor (TCR) therapeutics to combat cancer. The Basel-based biotech firm is a spin-off from the Department for Biosystems Science and Engineering (D-BSSE), likewise based in Basel, of the Swiss Federal Institute of Technology in Zurich (ETH). The company was incubated and initially financed via BaseLaunch, an incubator and accelerator operated by the investment and innovation promotion agency Basel Area Business & Innovation.

The seed financing round that has now closed was led by the Swiss venture capital fund Pureos Bioventures, a BaseLaunch partner, and Novo Seeds, the early-stage investment and company creation team of the Danish firm Novo Holdings. The gross proceeds from this financing round are, according to a press release, to be put towards further expanding the Engimmune pipeline, bolstering the research team in Switzerland and gaining a foothold in the Danish market.

Long-standing support from BaseLaunch

Engimmune has also announced the appointment of TCR pioneer and industry veteran Dr. Bent Jakobsen as Chairman of the Board. As part of the transaction, Dominik Escher and Jørgen Søberg Petersen will join the company as Board Directors, while Ximing Ding and João Ribas will join as observers.

“The long-standing support from BaseLaunch together with these industry-leading investors and the in-depth expertise of Bent gives Engimmune the standing to become a leading contributor to this competitive yet promising space”, explains Søren Mouritsen, CEO of Engimmune, in the press release.

“It was a real privilege to work alongside the team at Engimmune to help build the company from scratch”, comments Stephan Emmerth, BaseLaunch Director, in the press release.  This group of investors will enable the company “to continue developing their pioneering technology platforms to deliver truly differentiated TCR therapeutics”, he adds.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Novartis investing 100 million Swiss francs in new biologics center
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Novartis investing 100 million Swiss francs in new biologics center

The pharmaceutical company Novartis is investing a sum of 100 million Swiss francs in a new competence center for biologics...

Read More
Official opening of the competence center uptownBasel
Basel Area Business & Innovation, ICT, Innovation, Invest

Official opening of the competence center uptownBasel

uptownBasel celebrated its official opening. Technology companies such as Bouygues and Vinci Energies are already occupying the first building of...

Read More
Eight startups from Basel Area feature in TOP 100 Swiss Startups
Basel Area Business & Innovation, Innovation, Life Sciences / biotech, Medtech, Switzerland Innovation Park

Eight startups from Basel Area feature in TOP 100 Swiss Startups

Among the most promising startups in Switzerland eight companies from Basel Area's startup ecosystem have been named. They are some...

Read More
Roche opens tallest building in Switzerland
Basel Area Business & Innovation, Invest, Life Sciences / biotech

Roche opens tallest building in Switzerland

Roche has inaugurated a new office building with 3,200 positions in Basel. Standing 205 meters high, Building 2 is the...

Read More
DayOne Tech supports three medtech startups
Basel Area Business & Innovation, Innovation, Medtech, Switzerland Innovation Park

DayOne Tech supports three medtech startups

DayOne, the healthcare innovation initiative from Basel Area Business & Innovation, has started its medtech accelerator in the canton of...

Read More
Basel Area achieves milestone with settling of LifeMine
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel Area achieves milestone with settling of LifeMine

Life sciences company LifeMine Therapeutics from the USA has established its European headquarters in the Basel Area. With this, Basel...

Read More
1 2 3 27

Do you have a question? We'd like to hear from you.